Kevin Ness

Kevin Ness is a serial biotech entrepreneur and the CEO of Inscripta, Inc., a company at the forefront of gene-editing technology.4 With a LinkedIn username of "kevinness," he has a long history in the biotech industry and has been involved in several successful ventures.1

Career Highlights

Inscripta, Inc.: Kevin Ness currently leads Inscripta as its CEO.1 The company focuses on developing genome-editing tools and technologies. Under his leadership, Inscripta has achieved significant milestones:

• Raised $260 million in funding to develop and distribute their genome-editing device5
• Celebrated the one-year anniversary of MAD7, a key product or technology developed by the company2
• Secured additional funding, including a $20 million addition to their $105 million Series C round3

Previous Ventures: Before Inscripta, Kevin Ness co-founded and launched two other successful biotech companies:

• QuantaLife
• 10x Genomics4

Vision and Goals

Kevin Ness's primary objective is to "Build Blockbuster Products in Record Time".1 His focus at Inscripta aligns with this goal, as the company aims to create CRISPR-powered gene editing tools that could revolutionize the field of synthetic biology.56

Recognition

Ness's work has not gone unnoticed. He has mentioned that the Inscripta team received recognition from Colorado, likely for their innovations and contributions to the biotech industry.2

Kevin Ness's career demonstrates a consistent pattern of developing cutting-edge tools for biologists, with his current focus on making genome-editing technology widely accessible to scientists.56